secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2022-07-12T23:59:59+00:00
Accession:  0001193125-22-192006
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios appoints Brian Goff as CEO; Jackie Fouse transitions to Chair effective Aug 8, 2022
--------------------------------------------------------------------------------

- CEO Brian Goff appointed effective Aug 8, 2022; current CEO Jackie Fouse becomes Chair of Board.
- Goff receives $775K base salary, 70% target bonus, equity grants: $9M options, $5M PSUs, $2M RSUs.
- Goff also gets $250K relocation payment; equity awards vest over 3–4 years under Nasdaq inducement grant.
- Fouse's unvested equity continues to vest; she will not receive director equity awards in 2022.
- Former chair David Schenkein remains on board as director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522192006/0001193125-22-192006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522192006/d267394d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-192006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer